Products
Research Areas
COVID-19
Resources
Login
Quick Order
Cart
Login
Registration enables users to use special features of this website, such as past
order histories, retained contact details for faster checkout, review submissions, and special promotions.


Fields marked with a * are required.

Login
Quick Order
Contact Us

Locations


Orders Processing,
Shipping & Receiving,
Warehouse

2 Shaker Rd Suites
B001/B101
Shirley, MA 01464


Production Lab

Floor 6, Suite 620
20700 44th Avenue W
Lynnwood, WA 98036

Telephone Numbers



Tel: +1 (206) 374-1102
Fax: +1 (206) 577-4565

Contact Us



Additional Contact Details

Login
Registration enables users to use special features of this website, such as past
order histories, retained contact details for faster checkout, review submissions, and special promotions.


Fields marked with a * are required.

Login
Quick Order

KDR / VEGFR2 / FLK1

kinase insert domain receptor (a type III receptor tyrosine kinase)

Tyrosine-protein kinase that acts as a cell-surface receptor for VEGFA, VEGFC and VEGFD. Plays an essential role in the regulation of angiogenesis, vascular development, vascular permeability, and embryonic hematopoiesis. Promotes proliferation, survival, migration and differentiation of endothelial cells. Promotes reorganization of the actin cytoskeleton. Isoforms lacking a transmembrane domain, such as isoform 2 and isoform 3, may function as decoy receptors for VEGFA, VEGFC and/or VEGFD. Isoform 2 plays an important role as negative regulator of VEGFA- and VEGFC-mediated lymphangiogenesis by limiting the amount of free VEGFA and/or VEGFC and preventing their binding to FLT4. Modulates FLT1 and FLT4 signaling by forming heterodimers. Binding of vascular growth factors to isoform 1 leads to the activation of several signaling cascades. Activation of PLCG1 leads to the production of the cellular signaling molecules diacylglycerol and inositol 1,4,5-trisphosphate and the activation of protein kinase C. Mediates activation of MAPK1/ERK2, MAPK3/ERK1 and the MAP kinase signaling pathway, as well as of the AKT1 signaling pathway. Mediates phosphorylation of PIK3R1, the regulatory subunit of phosphatidylinositol 3-kinase, reorganization of the actin cytoskeleton and activation of PTK2/FAK1. Required for VEGFA-mediated induction of NOS2 and NOS3, leading to the production of the signaling molecule nitric oxide (NO) by endothelial cells. Phosphorylates PLCG1. Promotes phosphorylation of FYN, NCK1, NOS3, PIK3R1, PTK2/FAK1 and SRC.

Gene Name: kinase insert domain receptor (a type III receptor tyrosine kinase)
Family/Subfamily: Protein Kinase , VEGF Receptor
Synonyms: KDR, CD309, Fetal liver kinase 1, Fetal liver kinase-1, FLK-1, FLK1, Kinase insert domain receptor, Quek1, VEGFR, VEGFR2, Soluble VEGFR2, VEGF receptor 2, VEGFR-2, CD309 antigen, VEGF-R2
Target Sequences: NM_002253 NP_002244.1 P35968

Publications (11)

1
Receptor chimeras indicate that the vascular endothelial growth factor receptor-1 (VEGFR-1) modulates mitogenic activity of VEGFR-2 in endothelial cells. Rahimi N, Dayanir V, Lashkari K. The Journal of biological chemistry. 2000 275:16986-92. (WB, IP) [PubMed:10747927]
2
Vascular endothelial growth factor and hepatocyte growth factor levels are differentially elevated in patients with advanced retinopathy of prematurity. Lashkari K, Hirose T, Yazdany J, McMeel JW, Kazlauskas A, Rahimi N. The American journal of pathology. 2000 156:1337-44. (IHC-P; Human) [PubMed:10751359] [PMC:PMC1876877]
3
The carboxyl terminus controls ligand-dependent activation of VEGFR-2 and its signaling. Meyer RD, Singh AJ, Rahimi N. The Journal of biological chemistry. 2004 279:735-42. (WB, IP) [PubMed:14573614] [PMC:PMC1464116]
4
The carboxyl terminus of VEGFR-2 is required for PKC-mediated down-regulation. Singh AJ, Meyer RD, Band H, Rahimi N. Molecular biology of the cell. 2005 16:2106-18. (WB, IP) [PubMed:15673613] [PMC:PMC1073687]
5
Expression of periostin in human breast cancer. Puglisi F, Puppin C, Pegolo E, Andreetta C, Pascoletti G, D'Aurizio F, Pandolfi M, Fasola G, Piga A, Damante G, Di Loreto C. Journal of clinical pathology. 2008 61:494-8. [PubMed:17938160]
6
Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3. Hu-Lowe DD, Zou HY, Grazzini ML, Hallin ME, Wickman GR, Amundson K, Chen JH, Rewolinski DA, Yamazaki S, Wu EY, McTigue MA, Murray BW, Kania RS, O'Connor P, Shalinsky DR, Bender SL. Clinical cancer research : an official journal of the American Association for Cancer Research. 2008 14:7272-83. [PubMed:19010843]
7
Metabolic reprogramming by HIF-1 promotes the survival of bone marrow-derived angiogenic cells in ischemic tissue. Rey S, Luo W, Shimoda LA, Semenza GL. Blood. 2011 117:4988-98. [PubMed:21389314] [PMC:PMC3100705]
8
Molecular MRI differentiation of VEGF receptor-2 levels in C6 and RG2 glioma models. He T, Smith N, Saunders D, Pittman BP, Lerner M, Lightfoot S, Silasi-Mansat R, Lupu F, Towner RA. American journal of nuclear medicine and molecular imaging. 2013 3:300-11. (WB; Human) [PubMed:23901356] [PMC:PMC3715774] Related Antibodies: LS-C117508.
9
Reduced Microvascular Density in Omental Biopsies of Children with Chronic Kidney Disease. Burkhardt D, Bartosova M, Schaefer B, Grabe N, Lahrmann B, Nasser H, Freise C, Schneider A, Lingnau A, Degenhardt P, Ranchin B, Sallay P, Cerkauskiene R, Malina M, Ariceta G, Schmitt CP, Querfeld U. PloS one. 2016 November;11:e0166050. (Human) [Full Text Article] [PubMed:27846250] [PMC:PMC5113061] Related Antibodies: LS-C122532.
10
Zinc Finger Protein St18 Protects against Septic Death by Inhibiting VEGF-A from Macrophages. Kenta Maruyama, Hiroyasu Kidoya, Naoki Takemura, Erika Sugisawa, Osamu Takeuchi, Takeshi Kondo, Mohammed Mansour Abbas Eid, Hiroki Tanaka, Mikaël M Martino, Nobuyuki Takakura, Yasunori Takayama, Shizuo Akira, Alexis Vandenbon, Yutaro Kumagai. Cell reports. 2020 July;32:107906. [Full Text Article] [PubMed:32668247]
11
The gene expression of human endothelial cells is modulated by subendothelial extracellular matrix proteins: short-term response to laminar shear stress. Chlupac J, Filova E, Havlikova J, Matejka R, Riedel T, Houska M, Brynda E, Pamula E, R[Character e9]my M, Bareille R, Fernandez P, Daculsi R, Bourget C, Bacakova L, Bordenave L. Tissue engineering. Part A. 2014 Aug;20:2253-64. [Full Text Article] [PubMed:24606163] [PMC:PMC4137337] Related Antibodies: LS-C109100.
more

☰ Filters
Products
Proteins (34)
Over-Expression Lysate (2)
Recombinant (32)
KDR / VEGFR2 / FLK1 (34)
Bind (3)
ELISA (1)
Func (1)
SDS-PAGE (9)
No (34)
AVI-6His, C-terminus (1)
DDK,C-terminus (2)
Fc (3)
Fc, C-terminus (3)
GST (1)
GST, N-terminus (1)
His (5)
His, N-Terminal (1)
His,C-terminus (5)
His-GST (2)
His-GST, N-terminus (1)
His-S (1)
Human IgG Fc, C-terminus (4)
Myc-DDK (Flag) (2)
Human (22)
Mouse (7)
Pig (1)
Rat (3)
293F Cells (1)
293T Cells (1)
Baculovirus (2)
CHO Cells (1)
E. coli (5)
HEK 293 Cells (10)
Human (2)
Human Cells (7)
Mammalian Cells (2)
Sf9 Cells (2)
Wheat Germ Extract (1)
Purified (6)
Low endotoxin level (23)
Biologically active (8)
KDR / VEGFR2 / FLK1 Protein - Measured by its ability to inhibit the VEGF-dependent proliferation of human umbilical vein endothelial cells (HUVEC). The ED50 for this effect is typically 20-120 ng/mL in the presence of 10 ng/mL recombinant human VEGF165.
Select
HEK 293 Cells
Human IgG Fc, C-terminus
Bind ELISA Func SDS-PAGE
Biologically active
Less than 1.0 EU/µg protein (determined by LAL method).
The recombinant human VEGFR2/Fc is a disulfide-linked homodimeric protein. The reduced monomer consists of 979 amino acids and predicts a molecular mass of 109 kDa. The apparent molecular mass of rh VEGFR2/Fc monomer is approximatly 150-160 in SDS-PAGE under reducing conditions.
100 µg/$480; 1 mg/$2,324
KDR / VEGFR2 / FLK1 Protein - Recombinant Vascular Endothelial Growth Factor Receptor 2 By SDS-PAGE
Select
E. coli
His
32.7 kDa
10 µg/$268; 50 µg/$362; 100 µg/$577; 200 µg/$722; 1 mg/$1,755; 500 µg/$1,325; 5 mg/$2,708; 2 mg/$1,934
KDR / VEGFR2 / FLK1 Protein - Recombinant Vascular Endothelial Growth Factor Receptor 2 By SDS-PAGE
Select
E. coli
His-S
36.8 kDa
10 µg/$263; 50 µg/$343; 200 µg/$662; 100 µg/$530; 1 mg/$1,657; 500 µg/$1,242; 5 mg/$2,600; 2 mg/$1,832
KDR / VEGFR2 / FLK1 Protein - Measured by its ability to inhibit VEGF-dependent proliferation of human umbilical vein endothelial cells (HUVEC) in the presence of 10 ng/mL rhVEGF165. The ED50 for this effect is 40-120ng/mL.
Select
HEK 293 Cells
Human IgG Fc, C-terminus
SDS-PAGE
Biologically active
Less than 1.0 EU/µg protein (determined by LAL method).
The recombinant human KDR consists of 549 amino acids and predicts a molecular mass of 61.5 kDa.
200 µg/$633
KDR / VEGFR2 / FLK1 Protein - Measured by its ability to inhibit VEGF-dependent proliferation of human umbilical vein endothelial cells (HUVEC) in the presence of 10 ng/mL rhVEGF165. The ED50 for this effect is 20-80 ng/mL.
Select
HEK 293 Cells
Human IgG Fc, C-terminus
SDS-PAGE
Biologically active
Less than 1.0 EU/µg protein (determined by LAL method).
The recombinant human KDR consists of 449 amino acids and predicts a molecular mass of 50.4 kDa.
200 µg/$633
KDR / VEGFR2 / FLK1 Protein
Select
HEK 293 Cells
His,C-terminus
SDS-PAGE
Less than 1.0 EU/µg protein (determined by LAL method).
The recombinant human KDR consists of 319 amino acids and predicts a molecular mass of 35.9 kDa.
200 µg/$633
KDR / VEGFR2 / FLK1 Protein
Select
HEK 293 Cells
His,C-terminus
SDS-PAGE
Less than 1.0 EU/µg protein (determined by LAL method).
The recombinant human KDR consists of 219 amino acids and predicts a molecular mass of 24.8 kDa.
200 µg/$633
KDR / VEGFR2 / FLK1 Protein - Using the Octet RED System, the affinity constant (Kd) of VEGFR2 / KDR Protein, Human, Recombinant (His Tag) bound to Anti-VEGFR2 Antibody was 1.9 µM.
Select
HEK 293 Cells
His,C-terminus
Bind SDS-PAGE
Biologically active
Less than 1.0 EU/µg protein (determined by LAL method).
The secreted recombinant human VEGFR2 consists of 756 amino acids and predicts a molecular mass of 84.6 kDa. The apparent molecular mass of rhVEGFR2 is approximatly 120-130 in SDS-PAGE under reducing conditions.
100 µg/$480; 1 mg/$2,324
KDR / VEGFR2 / FLK1 Protein
Select
Baculovirus
His-GST, N-terminus
SDS-PAGE
Biologically active
Less than 1.0 EU/µg protein (determined by LAL method).
The recombinant human KDR /GST chimera consists of 787 amino acids and has a calculated molecular mass of 89.3 kDa. The recombinant protein migrates as an approximately 110 kDa band in SDS-PAGE under reducing conditions.
50 µg/$410; 500 µg/$1,735
KDR / VEGFR2 / FLK1 Protein - Recombinant Mouse VEGF Receptor 2/VEGF R2/FLK-1/KDR (C-Fc)
Select
Human
Fc, C-terminus
Less than 1.0 EU/µg protein (determined by LAL method).
110 kDa
10 µg/$273; 50 µg/$398
KDR / VEGFR2 / FLK1 Protein
Select
Sf9 Cells
DDK,C-terminus
83.3 kDa
20 µg/$677
KDR / VEGFR2 / FLK1 Protein
Select
Sf9 Cells
DDK,C-terminus
37.2 kDa
20 µg/$677
KDR / VEGFR2 / FLK1 Protein - Human VEGF Receptor 2/VEGF R2/FLK-1/KDR (C-6His-Avi) Biotinylated
Select
Human
AVI-6His, C-terminus
Less than 1.0 EU/µg protein (determined by LAL method).
86.1 kDa
20 µg/$416; 100 µg/$910
KDR / VEGFR2 / FLK1 Protein
Select
E. coli
GST
110.6 kD
1 mg/$1,355; 100 µg/$420; 20 µg/$323
KDR / VEGFR2 / FLK1 Protein - Recombinant Vascular Endothelial Growth Factor Receptor 2 By SDS-PAGE
Select
E. coli
His-GST
61.1 kDa
10 µg/$291; 50 µg/$502; 100 µg/$802; 200 µg/$1,002; 1 mg/$2,144; 500 µg/$1,668; 5 mg/$3,501; 2 mg/$2,334
KDR / VEGFR2 / FLK1 Protein
Select
HEK 293 Cells
His,C-terminus
SDS-PAGE
Less than 1.0 EU/µg protein (determined by LAL method).
The recombinant mouse KDR consists of 754 amino acids and predicts a molecular mass of 84.5 kDa. In SDS-PAGE under reducing conditions, the apparent molecular mass of rmKDR is approximately 100-110 kDa as a result of glycosylation.
100 µg/$441; 1 mg/$2,003
KDR / VEGFR2 / FLK1 Protein - Immobilized mouse VEGF164 at 10 µg/ml (100 µl/well) can bind mouse KDR-Fc, The EC50 of mouse KDR-Fc is 0.11-0.27 µg/ml.
Select
HEK 293 Cells
Human IgG Fc, C-terminus
Bind SDS-PAGE
Biologically active
Less than 1.0 EU/µg protein (determined by LAL method).
The recombinant mouse KDR /Fc comprises 984 amino acids and has a predicted molecular mass of 110 kDa. The apparent molecular mass of the protein is approximately 120 kDa in SDS-PAGE under reducing conditions due to glycosylation.
100 µg/$441; 1 mg/$2,003
Select
Human Cells
Fc
Less than 1.0 EU/µg protein (determined by LAL method).
109 kDa
100 µg/$926; 1 mg/$4,701
Select
Human Cells
Fc
Less than 1.0 EU/µg protein (determined by LAL method).
110 kDa
100 µg/$721
Select
Human Cells
His
Less than 1.0 EU/µg protein (determined by LAL method).
84.5 kDa
100 µg/$721
KDR / VEGFR2 / FLK1 Protein - 12.5% SDS-PAGE Stained with Coomassie Blue.
Select
Wheat Germ Extract
GST, N-terminus
10 µg/$479; 25 µg/$670
KDR / VEGFR2 / FLK1 Protein - Western validation with an anti-DDK antibody * L: Control HEK293 lysate R: Over-expression lysate
Select
293T Cells
Myc-DDK (Flag)
152 kDa
20 µg/$215
Select
Human Cells
His
Less than 1.0 EU/µg protein (determined by LAL method).
84.6 kDa
100 µg/$926; 1 mg/$4,701
KDR / VEGFR2 / FLK1 Protein - Western validation with an anti-DDK antibody * L: Control HEK293 lysate R: Over-expression lysate
Select
HEK 293 Cells
Myc-DDK (Flag)
152 kDa
100 µg/$710
Select
Human Cells
His
Less than 1.0 EU/µg protein (determined by LAL method).
84.3 kDa
50 µg/$721
Viewing 1-25 of 34 product results


Filtered By:
Products: Proteins


If you do not find the reagent or information you require, please contact Customer.Support@LSBio.com to inquire about additional products in development.

PLEASE NOTE

For RESEARCH USE ONLY. Intended for use by laboratory professionals. Not intended for human diagnostic or therapeutic purposes.

The data on this page has been compiled from LifeSpan internal sources, the National Center for Biotechnology Information (NCBI), and The Universal Protein Resource (UniProt).